Gram-positive bacterial infections

Summary

Gram-positive bacterial infections (MONDO:0021679) is a disease (an umbrella term covering 6 Mondo subtypes) and 44 clinical trials. Top therapeutic interventions include linezolid, daptomycin, and telavancin. A subtype of bacterial infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 6 Mondo subtypes
• Clinical trials: 44

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	gram-positive bacterial infections
Mondo ID	MONDO:0021679
MeSH	D016908
SNOMED CT	371582002
UMLS	C0085426
MedGen	39283
Is cancer (heuristic)	no

Also known as: bacterial infection, Gram-positive · bacterial infections, Gram Positive · bacterial infections, Gram-positive · bacterial infections, Gramme Positive · Gram Positive bacterial infections · Gram-positive bacterial infection · Gramme Positive bacterial infections · infection, Gram-positive bacterial · infections, Gram Positive bacterial · infections, Gram-positive bacterial · infections, Gramme Positive bacterial

Disease family

This is a subtype of bacterial infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › gram-positive bacterial infections

Related subtypes (51): primary bacterial infectious disease, commensal bacterial infectious disease, opportunistic bacterial infectious disease, chorioamnionitis, Clostridium difficile colitis, bacterial gastritis, bacterial arthritis, bacterial pneumonia, Whipple disease, Aeromonas hydrophila infectious disease, Pectobacterium carotovorum infection, Pseudomonas infection, septic peritonitis, bacterial infectious disease with sepsis, empyema, bacterial urinary tract infection, bacterial sexually transmitted disease, meningococcal infection, pasteurellosis, peritonsillar abscess, pneumonic pasteurellosis, tracheitis, Actinobacillus infectious disease, bacterial conjunctivitis, bacterial endocarditis, bacterial meningitis, Bifidobacteriales infectious disease, haemophilus infectious disease, Proteus infectious disease, pulpitis, rat-bite fever, Rickettsiosis, vibrio infectious disease, Yersinia infectious disease, bacterial myositis, noma, idiopathic severe pneumococcemia, necrotizing soft tissue infection, mycobacterial infectious disease, escherichia coli infection, gram-negative bacterial infections, spirochaetales infections, skin disease caused by bacterial infection, staphylococcal infection, anaerobic bacteria infectious disease, Klebsiella infectious disease, fournier gangrene, botryomycosis, bacterial hemorrhagic fever, Mycoplasmoides infection, Enterococcus infectious disease

Subtypes (6): Erysipelothrix infectious disease, Actinomycetales infectious disease, Bacillaceae infectious disease, streptococcal infection, Clostridium infectious disease, infection caused by Bifidobacterium

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated or in trials for this disease

1 approved drug — disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Status
Daptomycin	Approved (phase 4)

10 drugs in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

Drug	Highest phase
Cefazolin	Phase 3
Dicloxacillin	Phase 3
Linezolid	Phase 3
Oxacillin	Phase 3
Quinupristin/Dalfopristin	Phase 3
Tigecycline	Phase 3
Vancomycin	Phase 3
Cloxacillin	Phase 2
Nafcillin	Phase 2
Telavancin	Phase 2

Clinical trials & evidence

Clinical trials

Clinical trials: 44.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	13
PHASE3	10
PHASE2	9
PHASE1	6
PHASE4	4
PHASE2/PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00147511	PHASE4	COMPLETED	Time To Efficacy and Onset Of Action Of Linezolid
NCT00406198	PHASE4	COMPLETED	Impact of Continuous Venovenous Haemofiltration on Organ Failure During the Early Phase of Severe Sepsis
NCT03438214	PHASE4	UNKNOWN	Effect of Intermittent Infusion Versus Continuous Infusion of Vancomycin on Kidney Failure in Critically Ill Patients
NCT03982030	PHASE4	WITHDRAWN	Dalbavancin Outpatient Pilot
NCT06444802	PHASE3	NOT_YET_RECRUITING	Model-informed Precision Dosing for Linezolid
NCT06592586	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women
NCT00035269	PHASE3	COMPLETED	New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)
NCT00037050	PHASE3	COMPLETED	Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria
NCT00055198	PHASE3	TERMINATED	Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria
NCT00079976	PHASE3	COMPLETED	Study Evaluating Tigecycline in Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA)
NCT00081744	PHASE3	COMPLETED	Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized Subjects
NCT00108433	PHASE3	TERMINATED	Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections
NCT00240747	PHASE3	TERMINATED	Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric Patients
NCT00529282	PHASE3	TERMINATED	A Study of Ceftobiprole in Patients With Fever and Neutropenia.
NCT03896685	PHASE3	COMPLETED	Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)
NCT04847921	PHASE2/PHASE3	TERMINATED	Substance Use Disorder (SUD)-Associated Infections’ Treatment With Dalbavancin ENabling OUtpatient Transition
NCT07550595	PHASE2	NOT_YET_RECRUITING	Oritavancin for Treatment of Serious Cardiac Infections
NCT00061633	PHASE2	COMPLETED	Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
NCT00062647	PHASE2	COMPLETED	Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia
NCT00077675	PHASE2	COMPLETED	Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
NCT01212432	PHASE2	UNKNOWN	Daptomycin Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-venous Hemodiafiltration, a Dose Finding Study
NCT01412801	PHASE2	COMPLETED	Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings
NCT01446289	PHASE2	COMPLETED	Immune Response Induced by a Vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their Offsprings
NCT03747497	PHASE2	COMPLETED	Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection
NCT03964493	PHASE2	COMPLETED	TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection
NCT00136292	PHASE1	COMPLETED	Study of Single Dose Daptomycin in Pediatric Patients With Gram-positive Infection for Which They Are Receiving Standard Antibiotics
NCT01019395	PHASE1	COMPLETED	Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics
NCT02013141	PHASE1	TERMINATED	Telavancin Pediatric PK Study (Ages >12 Months to 17 Years)
NCT02134301	PHASE1	COMPLETED	Open Label, Dose-finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Participants With Suspected or Confirmed Bacterial Infections
NCT02750761	PHASE1	COMPLETED	A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013)
NCT03361163	PHASE1	COMPLETED	Controlled Human Infection for Vaccination Against Streptococcus Pyogenes
NCT05824988	Not specified	RECRUITING	Drug Exposure and Minimum Inhibitory Concentration in the Treatment of MAC Lung Disease
NCT07013552	Not specified	NOT_YET_RECRUITING	Oritavancin for CIED Infections With MDR Gram-positive Cocci
NCT00167960	Not specified	COMPLETED	Study Evaluating Vancomycin-Resistant Enterococci in a Hematology Unit
NCT00167999	Not specified	COMPLETED	Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units
NCT00501150	Not specified	COMPLETED	Oral Antibiotic Treatment at Home Instead of Intravenous Treatment in Hospital for Resistant Gram Positive Infections
NCT00736554	Not specified	COMPLETED	What is the Prevalence of Methicillin-Resistant Staphylococcus Aureus in Skin and Soft Tissue Infections Presenting to the Emergency Departments of a Canadian Academic Health Care Center?
NCT00835783	Not specified	TERMINATED	Validation Study of Combined Positron Emission Tomography/Computer Tomography to Diagnose Infection and Inflammation
NCT00874367	Not specified	COMPLETED	Early-Onset Sepsis Surveillance Study
NCT01564758	Not specified	COMPLETED	Post Marketing Surveillance Study on Linezolid

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
LINEZOLID	4	6
DAPTOMYCIN	4	4
TELAVANCIN	4	4
ORITAVANCIN	4	3
CEFTOBIPROLE MEDOCARIL FREE ACID	4	2
DALBAVANCIN	4	2
OXACILLIN	4	2
PIPERACILLIN	4	2
TIGECYCLINE	4	2
VANCOMYCIN	4	2
BEDAQUILINE	4	1
DICLOXACILLIN	4	1
NAFCILLIN	4	1
TEDIZOLID	4	1
CONTEZOLID ACEFOSAMIL	3	1
QUINUPRISTIN/DALFOPRISTIN	3	1
RIFAQUIZINONE	2	1
CHEMBL1649722	0	4
CHEMBL4286784	0	4
CHEMBL4744444	0	4
CHEMBL4802121	0	4
CHEMBL5271499	0	4
CHEMBL4778239	0	2
CHEMBL4785392	0	2
CHEMBL6174705	0	2
CHEMBL4299436	0	2
CHEMBL6175829	0	1
17	0	1